How particle surface properties affect inflammation in the lungs
Role of particle surface functionalization in inflammation
This study looks at how tiny particles, like those in silica and asbestos, affect lung health and inflammation, aiming to understand how they interact with immune cells to help find better treatments for lung diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-11062382 on NIH RePORTER |
What this research studies
This research investigates how the surface characteristics of micron-sized particles, such as those found in silica and asbestos, influence inflammation and lung health. By examining the interactions between engineered nanomaterials and immune cells, particularly alveolar macrophages, the study aims to uncover the mechanisms that lead to lung diseases. The approach includes analyzing how different particle properties affect cell function and inflammatory responses in laboratory models. This could provide insights into potential therapeutic targets for treating lung and systemic diseases caused by these exposures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of exposure to harmful micron-sized particles, such as those working in construction or mining industries.
Not a fit: Patients with lung diseases not related to particle exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating lung diseases associated with particle exposure.
How similar studies have performed: Previous research has shown that understanding the interactions between particles and immune cells can lead to significant advancements in treating related diseases.
Where this research is happening
Missoula, United States
- University of Montana — Missoula, United States (Active)
Researchers
- Principal investigator: Holian, Andrij — University of Montana
- Study coordinator: Holian, Andrij
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.